Dr. Gulam Manji presented results from a phase II clinical trial testing a combination therapy for resectable gastric cancer or gastroesophageal junction (GEJ) cancer at this year’s AACR conference.
Congratulations to Dr. Joel Gabre, recipient of a 2022 Research Scholar Award from the American Gastroenterological Association (AGA) Research Foundation.
In Notes from the Lab, we spotlight the Giancotti lab and new research identifying factors that sustain prostate cancer cells that have become resistant to androgen receptor (AR) therapy.
A new instrument at Columbia will help scientists uncover the full potential of heavy ion radiation therapy and could improve treatment of pancreatic cancer and other difficult-to-treat tumors.
"My role is to ... be more than just the connector in the community, but also the link between the clinical world and the community," says HICCC Community Advisory Board Member Dr. Ginny Mantello.
“Normalizing mental health treatment as an integral component of your overall cancer care may also go a long way,” said the Cancer Center's Nathalie Moise, MD, MS.
A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.
In this new content series, Reflections, Dr. Lisa A. Kachnic discusses advances in radiation oncology and the innovation happening now that will have a direct impact on patient care.
The U.S. Preventative Services Task Force now recommends that colon cancer screening start at age 45, with increasing numbers of young people with colon cancer becoming a troubling trend.
Researchers have developed a “cloaking” system that temporarily hides therapeutic bacteria from immune systems, enabling them to more effectively deliver drugs to tumors and kill cancer cells.
